A Case of Anti-Synthetase Syndrome Successfully Treated with Mycophenolate Mofetil and Rituximab but No Corticosteroids.

Unlabelled: A patient with antisynthetase syndrome with pulmonary and muscular involvement was treated with immunosuppressive agents without corticosteroids. Rituximab was added to mycophenolate mofetil therapy with improvement in lung functional and imaging findings and normalization of creatine kinase levels.

Learning Points: Antisynthetase syndrome associated with interstitial lung disease (ILD) and myopathy can be successfully treated without corticosteroids.

Frailty assessment for COVID-19 follow-up: a prospective cohort study.

Background: The Clinical Frailty Scale (CFS) is increasingly used for clinical decision making in acute care but little is known about frailty after COVID-19.

Objectives: To investigate frailty and the CFS for post-COVID-19 follow-up.

Methods: This prospective multicentre cohort study included COVID-19 survivors aged ≥50 years presenting for a follow-up visit ≥3 months after the acute illness.

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study.

Background: The infectious coronavirus disease 2019 (COVID-19) pandemic is an ongoing global healthcare challenge. Up to one-third of hospitalised patients develop severe pulmonary complications and acute respiratory distress syndrome. Pulmonary outcomes following COVID-19 are unknown.

[Current approach to bronchial carcinoid tumors].

Neuroendocrine tumors of the lung comprise typical and atypical carcinoids, as well as large cell neuroendocrine carcinomas and small cell carcinomas. However carcinoid tumours differ from the latter two by their clinical presentation, radiographic, histological appearances, and treatment modalities as well as prognosis. In this paper we review these features and discuss the role of new imaging modalities such as PET scan.